Profiel
Mark Toomey is President at Canton Strategic Holdings, Inc. since 2025.
Former roles include Head-North America Asset Management Sales at Galaxy Digital Holdings, Inc. from 2021 to 2025, and Managing Director-Equity Institutional Derivatives at The Goldman Sachs Group, Inc. Education includes an undergraduate degree from Syracuse University and an MBA from Georgetown University.
Actieve functies van Mark Toomey
| Bedrijven | Functie | Begin |
|---|---|---|
| CANTON STRATEGIC HOLDINGS, INC. | President | 06-11-2025 |
Eerdere bekende functies van Mark Toomey
| Bedrijven | Functie | Einde |
|---|---|---|
Galaxy Digital Holdings Ltd.
Galaxy Digital Holdings Ltd. Investment Banks/BrokersFinance Engages in crypto trading, lending, advisory and mining, custody platform & block chain infrastructure development and asset management business | Verkoop & Marketing | 01-02-2025 |
| THE GOLDMAN SACHS GROUP, INC. | Corporate Officer/Principal | - |
Opleiding van Mark Toomey
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 5 |
|---|---|
The Goldman Sachs Group, Inc.
The Goldman Sachs Group, Inc. Investment Banks/BrokersFinance Provides investment banking, asset, wealth management and platform services | Finance |
Syracuse University
Syracuse University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Georgetown University
Georgetown University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Galaxy Digital Holdings Ltd.
Galaxy Digital Holdings Ltd. Investment Banks/BrokersFinance Engages in crypto trading, lending, advisory and mining, custody platform & block chain infrastructure development and asset management business | Finance |
Tharimmune, Inc.
Tharimmune, Inc. BiotechnologyHealth Technology Operates as a pre-clinical biotechnology company that develops novel therapeutic candidates targeting ferroptosis | Health Technology |
















